The role of extended lymphadenectomy for adenocarcinoma of the head of the pancreas: strength of the evidence.
With improvements in the safety of Whipple resection in recent decades, surgeons have continued to explore the role of more extensive lymphadenectomy in hope of improving long-term survival. A systematic literature search of level I evidence addressing the role of the extent of lymphadenectomy was undertaken. Only reports of prospective, randomized controlled trials comparing pancreaticoduodenectomy with standard lymphadenectomy to pancreaticoduodenectomy with extended lymphadenectomy where information regarding survival, morbidity, mortality, the number of resected lymph nodes in each group and detailed operative technique were included. Four prospective, randomized trials comprising some 424 patients and one meta-analysis were identified. In aggregate, these studies confirmed that the number of resected lymph nodes was significantly higher in the pancreaticoduodenectomy with extended lymphadenectomy group. Morbidity and mortality rates were comparable. Postoperative diarrhea in the early months after operation was problematic in patients undergoing extended lymphadenectomy. In none of the studies was a benefit in long-term survival demonstrated. Standard pancreaticoduodenectomy continues to be the operation of choice for adenocarcinoma of the head of the pancreas.
Farnell
Michael B
MB
Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. farnell.michael@mayo.edu
Aranha
Gerard V
GV
Nimura
Yuji
Y
Michelassi
Fabrizio
F
D000230:Adenocarcinoma / Q000601:surgery*; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods*; D015201:Meta-Analysis as Topic; D010190:Pancreatic Neoplasms / Q000601:surgery*; D016577:Pancreaticoduodenectomy; D016032:Randomized Controlled Trials as Topic